Cholesterol Pills for Kids?
Recently, there was an outcry about new recommendations from the American Academy of Pediatrics that suggest giving kids as young as 8 years old cholesterol-reducing statin drugs.
Tara Parker-Pope discusses the controversy in a recent column. Those who object to the new recommendations worry about the drugs' long-term consequences, the AAP's financial relationships with drug companies and the possibility that the new guidelines will lead to overuse of the drugs. The defenders argue that the guidelines specify that only a very small group of children--those with strong genetic and lifestyle risk factors--would even be considered for statin therapy. Parker-Pope's whole article is worth reading, as it discusses both the financial and the medical aspects to this debate.
One problem here is widespread throughout medicine: what some have called "indication sprawl." Once a drug or treatment is recommended for one narrow category of patients, it tends to get indicated for more and more categories with less and less testing and justification for the new categories. But more profit for the drug makers.
